ACRS
Price
$1.46
Change
+$0.05 (+3.55%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
154.3M
35 days until earnings call
PACB
Price
$1.49
Change
+$0.20 (+15.50%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
976.68M
28 days until earnings call
Interact to see
Advertisement

ACRS vs PACB

Header iconACRS vs PACB Comparison
Open Charts ACRS vs PACBBanner chart's image
Aclaris Therapeutics
Price$1.46
Change+$0.05 (+3.55%)
Volume$10.78K
Capitalization154.3M
Pacific Biosciences of California
Price$1.49
Change+$0.20 (+15.50%)
Volume$177K
Capitalization976.68M
ACRS vs PACB Comparison Chart in %
Loading...
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACRS vs. PACB commentary
Jul 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a Buy and PACB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 03, 2025
Stock price -- (ACRS: $1.41 vs. PACB: $1.29)
Brand notoriety: ACRS and PACB are both not notable
ACRS represents the Biotechnology, while PACB is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ACRS: 76% vs. PACB: 191%
Market capitalization -- ACRS: $154.3M vs. PACB: $976.68M
ACRS [@Biotechnology] is valued at $154.3M. PACB’s [@Medical Specialties] market capitalization is $976.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B. The average market capitalization across the [@Medical Specialties] industry is $8.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACRS’s FA Score shows that 1 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).

  • ACRS’s FA Score: 1 green, 4 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, ACRS is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACRS’s TA Score shows that 4 TA indicator(s) are bullish while PACB’s TA Score has 5 bullish TA indicator(s).

  • ACRS’s TA Score: 4 bullish, 5 bearish.
  • PACB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PACB is a better buy in the short-term than ACRS.

Price Growth

ACRS (@Biotechnology) experienced а -7.24% price change this week, while PACB (@Medical Specialties) price change was +7.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +33.64%, and the average quarterly price growth was +2.14%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.68%. For the same industry, the average monthly price growth was +2.37%, and the average quarterly price growth was -0.79%.

Reported Earning Dates

ACRS is expected to report earnings on Aug 06, 2025.

PACB is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (+1.68% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PACB($977M) has a higher market cap than ACRS($154M). PACB YTD gains are higher at: -29.508 vs. ACRS (-43.145). ACRS has higher annual earnings (EBITDA): -53.49M vs. PACB (-277.28M). PACB has more cash in the bank: 631M vs. ACRS (105M). PACB has higher revenues than ACRS: PACB (201M) vs ACRS (17.8M).
ACRSPACBACRS / PACB
Capitalization154M977M16%
EBITDA-53.49M-277.28M19%
Gain YTD-43.145-29.508146%
P/E RatioN/AN/A-
Revenue17.8M201M9%
Total Cash105M631M17%
Total DebtN/A934M-
FUNDAMENTALS RATINGS
ACRS vs PACB: Fundamental Ratings
ACRS
PACB
OUTLOOK RATING
1..100
5122
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6248
P/E GROWTH RATING
1..100
10079
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACRS's Valuation (21) in the Pharmaceuticals Other industry is significantly better than the same rating for PACB (100) in the Biotechnology industry. This means that ACRS’s stock grew significantly faster than PACB’s over the last 12 months.

ACRS's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as PACB (100) in the Biotechnology industry. This means that ACRS’s stock grew similarly to PACB’s over the last 12 months.

ACRS's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as PACB (99) in the Biotechnology industry. This means that ACRS’s stock grew similarly to PACB’s over the last 12 months.

PACB's Price Growth Rating (48) in the Biotechnology industry is in the same range as ACRS (62) in the Pharmaceuticals Other industry. This means that PACB’s stock grew similarly to ACRS’s over the last 12 months.

PACB's P/E Growth Rating (79) in the Biotechnology industry is in the same range as ACRS (100) in the Pharmaceuticals Other industry. This means that PACB’s stock grew similarly to ACRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACRSPACB
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 6 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KYOCF10.42N/A
N/A
Kyocera Corp.
MTLK0.30N/A
N/A
Metalink Ltd.
XPPLF9.94N/A
N/A
XP Power Ltd.
LIFD0.39N/A
N/A
LFTD Partners Inc.
AMBFF15.40-0.19
-1.19%
Ambu A/S

ACRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with PLLWF. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then PLLWF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACRS
1D Price
Change %
ACRS100%
-0.70%
PLLWF - ACRS
64%
Loosely correlated
N/A
STRRP - ACRS
52%
Loosely correlated
+0.38%
MYNZ - ACRS
40%
Loosely correlated
+0.71%
UFPT - ACRS
39%
Loosely correlated
+3.36%
IBRX - ACRS
34%
Loosely correlated
-2.65%
More